© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
August 24, 2022
Due to suspected cases of fatal differentiation syndrome in a clinical trial, the FDA has placed a full clinical hold on the study of FHD-286 in acute myeloid leukemia and myelodysplastic syndrome.
A phase 1b/2 clinical trial aims to evaluate the safety of lanraplenib plus gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
August 19, 2022
According to results from the QuANTUM-First, quizartinib significantly improved overall survival vs standard of care in patients with newly diagnosed FLT3 ITD–positive acute myeloid leukemia.
August 17, 2022
Siddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.
August 02, 2022
Marcin Kortylewski, PhD, discusses what research he believes is next to come in the acute myeloid leukemia space.
July 15, 2022
Siddhartha Mukherjee, MD, explains the current golden standard for frontline treatment of patients with acute myeloid leukemia.
June 28, 2022
In a phase 1 clinical trial, treatment with GFH009 showed early signal s of efficacy in patients with advanced relapsed or refractory lymphoma and acute myeloid leukemia.
June 27, 2022
Gilteritinib monotherapy reacts favorably and led to higher rates of composite complete remissions in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia who received prior midostaurin or sorafenib.
June 14, 2022
Marcin Kortylewski, PhD, discusses some of the goals and findings of his research on blocking STAT3 in acute myeloid leukemia cells.
June 04, 2022
According to , results from a phase 1 study support that on-target magrolimab-mediated anemia is manageable in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.